Thalidomide, peginterferon alfa-2b and ribavirin in the treatment of non-responder patients with chronic hepatitis C genotype 1: A pilot study;Talidomida, peginterferón alfa-2b y ribavirina en el tratamiento de pacientes no respondedores con hepatitis crónica C genotipo 1: Estudio piloto

Revista Espanola de Enfermedades Digestivas

Volumn 103, Issue 12, 2011, Pages 619-625

  Pardo Yules, Benjamín ^a   Gallego Durán, Rocío ^a   Eslam, Mohammed ^a   García Collado, Carlos ^a   Grande, Lourdes ^a   Paradas, Carmen ^a   Morillo, Ramón ^a   Dorantes, Benito ^a   Romero Gómez, Manuel ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

Author keywords

Clinical trial; Hepatitis C; Host factors; Thalidomide; TNF

Indexed keywords

ALANINE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; PEGINTERFERON ALPHA2B; RIBAVIRIN; THALIDOMIDE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ELASTOGRAPHY; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; IMMUNOMODULATION; LIVER FIBROSIS; MALE; NEUROPATHY; PHENOTYPE; VIRUS LOAD;

EID: 84255167731     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: 10.4321/S1130-01082011001200003     Document Type: Article

References (56)

1. World Health Organization. Hepatitis C. Fact sheet number 164, revised October 2000. Available at: http://www.who.int/mediacentre/factss-heets/ fs164len, accessed March 6, 2009.
2. Puig del Castillo I, Miquel Planas M, Vergara Gómez M, Cebollero Agustí A, Gallach Montero M, Dalmau Obrador B, et al. Five-year follow-up of patients with chronic C hepatitis and sustained virological response. Rev Esp Enferm Dig 2011;103:56-61.
3. Fried MW, Jensen DM, Rodríguez-Torres M, Nyberg LM, Di Bisceglie AM, Morgan TR, et al. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon -2a and ribavirin. Hepatology 2008;48:1033-43.
4. Cuenca F, Fernández C, Devesa MJ, López-Alonso G, Mayol J, Suárez A, et al. Predictive baseline criteria of primary therapeutic failure in chronic hepatitis C genotype 1. Rev Esp Enferm Dig 2010;102(4):234-8.
5. Aguilar Reina J. Viral dynamics and prediction of response to treatment with pegylated interferon and ribavirin in patients with chronic hepatitis C. Rev Esp Enferm Dig 2009;101:665-70.
6. Larrubia JR, Benito-Martínez S, Miquel-Plaza J, Sanz-de-Villalobos E, González-Mateos F, Parra T. Cytokines -their pathogenic and the-rapeutic role in chronic viral hepatitis. Rev Esp Enferm Dig 2009; 101:343-51.
7. Pestka S. The human interferon alpha species and receptors. Biopolymers 2000;55:254-87.
8. Asselah T, Estrabaud E, Bieche I, Lapalus M, De Muynck S, Vidaud M, et al. Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int 2010;30(9):1259-69.
9. Krebs DL, Hilton DJ. SOCS: physiological suppressors of cytokine signaling. J Cell Sci 2000;113:2813-9.
10. Walsh MJ, Jonsson JR, Richardson MM, Lipka GM, Purdie DM, Clouston AD, et al. Non-response to antiviral therapy is associated with obe- sity and increased hepatic expression of suppressor of cytokine signa- lling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006;55:529-35.
11. Shen X, Hong F, Nguyen VA, Gao B. IL-10 attenuates IFN-alpha-activated STAT1 in the liver: involvement of SOCS2 and SOCS3. FEBS Lett 2000;480:132-6.
12. Hong F, Nguyen VA, Gao B. Tumor necrosis factor alpha attenuates interferon alpha signaling in the liver: involvement of SOCS3 and SHP2 and implication in resistance to interferon therapy. FASEB J 2001;15: 1595-7.
13. Fontana RJ. Nonresponders to hepatitis C virus antiviral therapy: pegylated interferons and beyond. Gastroenterol Clin North Am 2004; 33(3):527-47.
14. Jacobson IM. Treatment options for patients with chronic hepatitis C not responding to initial antiviral therapy. Clin Gastroenterol Hepatol 2009;7(9):921-30.
15. Zeuzem S, Berg T, Moeller B, Hinrichsen H, Mauss S, Wedemeyer H, et al. Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat 2009;16(2):75-90.
16. Lange CM, Sarrazin C, Zeuzem S. Review article: specifically targeted anti-viral therapy for hepatitis C - a new era in therapy. Aliment Phar- macol Ther 2010;32(1):14-28.
17. Thompson A, Patel K, Tillman H, McHutchison JG. Directly acting antivirals for the treatment of patients with hepatitis C infection: a clinical development update addressing key future challenges. J Hepatol 2009;50(1):184-94.
18. Kieffer TL, Kwong AD, Picchio GR. Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). J Antimicrob Chemother 2010;65(2):202-12.
19. Khattab MA. Targeting host factors: a novel rationale for the management of hepatitis C virus. World J Gastroenterol 2009,15(28):3472-9.
20. Kumar A, Galeb S, Djulbegovic B. Treatment of patients with multiple myeloma: an overview of systematic reviews. Acta Haematol 2011; 125(1-2):8-22.
21. Forno C, Häusermann P, Hatz C, Itin P, Blum J. The difficulty in diagnosis and treatment of leprosy. J Travel Med 2010;17(4):281-3.
22. Paravar T, Lee DJ. Thalidomide: mechanisms of action. Int Rev Immunol 2008; 27 (3):111-35.
23. De Sanctis JB, Mijares M, Suárez A, Compagnone R, Garmendia J, More-no D, et al. Pharmacological properties of thalidomide and its analogues. Recent Pat Inflamm Allergy Drug Discov 2010;4(2):144-8.
24. Milazzo L, Biasin M, Gatti N, Piacentini L, Niero F, Zanone Poma B, et al. Thalidomide in the treatment of chronic hepatitis C unresponsive to alfa-interferon and ribavirin. Am J Gastroenterol 2006; 101:399-402.
25. Caseiro MM. Treatment of chronic hepatitis C in non-responsive patients with pegylated interferon associated with ribavirin and thali- domide: report of six cases of total remission. Rev Inst Med Trop Sao Paulo 2006;48:109-12.
26. Weeber M, Vos R, Klein H, De Jong-Van Den Berg LT, Aronson AR, Molema G. Generating hypotheses by discovering implicit associations in the literature: a case report of a search for new potential therapeutic uses for thalidomide. J Am Med Inform Assoc 2003;10:252-9.
27. AIDS Clinical Trials Group. AIDS Clinical Trials Group (ACTG) Toxicity Grading Scale. Silver Spring, MD: AIDS Clinical Trials Group, 2004.
28. Romero-Gómez M, Gómez-González E, Madrazo A, Vera-Valencia M, Rodrigo L, Pérez-Alvarez R, et al. Optical analysis of computed tomography images of the liver predicts fibrosis stage and distribution in chronic hepatitis C. Hepatology 2008;47:810-6.
29. Diago M, Crespo J, Olveira A, Pérez R, Bárcena R, Sánchez-Tapias JM et al. Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon alpha-2a in hepatitis C virus genotype 1 true non-responder patients. Aliment Phar-macol Ther 2007;26:1131-8.
30. Jensen DM, Marcellin P, Freilich B, Andreone P, Di Bisceglie A, Brandão-Mello CE et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med. 2009;150(8):528-40.
31. Kaiser S, Hass H, Lutze B, et al. Comparison of daily consensus interferon versus peginterferon alfa 2a extended therapy of 72 weeks for peginterferon/ribavirin relapse patients with chronic hepatitis C. Gastroenterology 2006;130(Supl. 2):A-784, abstract S1060.
32. Steffen M, Cornberg M, Buggisch P. Treatment of chronic hepatitis C with consensus interferon in relapsers and non-responders to interferon-based therapy. Hepatogastroenterology 2007;54:2368-72.
33. Nelson DR, Rustgi V, Balan V, Sulkowski MS, Davis GL, Muir AJ, et al. Safety and antiviral activity of albinterferon alfa-2b in prior inter- feron nonresponders with chronic hepatitis C. Clin Gastroenterol Hepatol 2009;7:212-8.
34. Rustgi VK, Esposito S, Hamzeh FM, Shiffman ML. Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin. Aliment Pharmacol Ther 2008 1;27(5):433-40.
35. Jensen DM, Freilich B, Andreone P, Andreone P, Di Bisceglie A, Brandão-Mello CE, et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon alfa-2b. Ann Int Med 2009; 150:528-40.
36. McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH et al. Telaprevir for previously treated chronic HCV infec- tion. N Engl J Med. 2010; 362:1292-303.
37. Yasumoto T, Murata M, Oshima Y. Diarrhetic shellfish toxins. Tetrahedron 1985;41:1019-25.
38. Beutler B, Cerami A. The biology of cachectin/TNF-a primary mediator of the host response. Annu Rev Immunol 1989;7:625-55.
39. Farinati F, Cardin R, De Maria N, Della Libera G, Marafin C, Lecis E, et al. Iron storage, lipid peroxidation and glutathion turnover in chronic anti-HCV positive hepatitis. J Hepatol 1995;22:449-56.
40. Fukuda R, Ishimura N, Ishihara S, Chowdhury A, Morlyama N, Nogami C, et al. Intrahepatic expression of pro-inflammatory cytokine mRNAs and interferon efficacy in chronic hepatitis C. Liver 1996;16:390-9.
41. Dai CY, Chuang WL, Chang WY, Chen SC, Lee LP, Hsieh MY, et al. Tumor necrosis factor- alpha promoter polymorphism at position -308 predicts response to combination therapy in hepatitis C virus infection. J Infect Dis 2006;193(1):98-101.
42. Dumoulin FL, Wennrich U, Nischalke HD, Leifeld L, Fischer HP, Sauerbruch T, et al. Intrahepatic mRNA levels of interferon gamma and tumor necrosis factor alpha and response to antiviral treatment of chronic hepatitis C. J Hum Virol 2001;4:195-9.
43. Zein NN. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: A phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005;42:315-22.
44. Nathan DM, Angus PW, Gibson PR. Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J Gastroenterol Hepatol 2006;21:1366-71.
45. Lin JH, Yang X, Bostrom MP. Thalidomide blocking of particle-induced TNFalpha release in vitro. J Orthop Sci 2003;8(1):79-83.
46. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991;173(3):699-703.
47. Yeh TS, Ho YP, Huang SF, Yeh JN, Jan YY, Chen MF. Thalidomide salvages lethal hepatic necroinflammation and accelerates recovery from cirrhosis in rats. J Hepatol 2004;41:606-12.
48. Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004;126:1015-23.
49. Jacobson IM, Gonzalez SA, Ahmed F, Lebovics E, Min AD, Boden-heimer HC Jr, et al. A randomized trial of pegylated interferon alpha- 2b plus ribavirin in the retreatment of chronic hepatitis C. Am J Gastroenterol 2005;100:2453-62.
50. Gross J, Johnson S, Kwo P, et al. Double-dose peginterferon alpha-2b with weight-based ribavirin improves response for interferon/ ribavirin nonresponders with hepatitis C: final results of "RENEW."Hepatology 2005;42(Supl. 1):219A.
51. Reuter S, Schnekenburger M, Cristofanon S, Buck I, Teiten MH, Dau-beuf S, Eifes S, et al. Tumor necrosis factor alpha induces gamma-glu- tamyl transferase expression via nuclear factor-kappaB in cooperation with Sp1. Biochem Pharmacol 2009;77:397-411.
52. Spahr L, Giostra E, Frossard JL, Bresson-Hadni S, Rubbia-Brandt L, Hadengue A. Soluble TNF-R1, but not tumor necrosis factor alpha, predicts the 3-monthmortality in patients with alcoholic hepatitis. J Hepatol 2004;41:229-34.
53. Isoardo G, Bergui M, Durelli L, Barbero P, Boccadoro M, Bertola A, et al. Thalidomide neuropathy: clinical, electrophysiological and neu- roradiological features. Acta Neurol Scand 2004;109:188-93.
54. Cavaletti G, Beronio A, Reni L, Ghiglione E, Schenone A, Briani C, et al. Thalidomide sensory neurotoxicity: a clinical and neurophysio- logic study. Neurology 2004;62:2291-3.
55. Khiani V, Kelly T, Shibli A, Jensen D, Mohanty SR. Acute inflammatory demyelinating polyneuropathy associated with pegylated interferon alpha 2a therapy for chronic hepatitis C virus infection. World J Gastroenterol 2008;14:318-21.
56. Kato-Motozaki Y, Komai K, Takahashi K, Ishida C, Ueda M, Kusunoki S, et al. Polyethylene glycol interferon alpha-2b-induced immune- mediated polyradiculoneuropathy. Intern Med 2009;48:569-72.